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" W4b Stromal cells of the bone marrow are a
hairii b'-i"een 'sh 'w seeptibk qtoroximixed population of interactive cells con-
l2tbohsisting primarily of fibroblasts and macro-
phages (1-3). These cells are a critical tar-
'2e:2'e{,,,E,-_,°,,E,._eg get oftoxicity because they are an essential
component
vironment that contributes to the normal
regulation of hematopoiesis (1,4). The
qufl~ sensitivity of stromal cells has been ob-
wjro- msiu¢ em'rme~ end 0''' served in a series of experiments demon-
strating that hydroquinone (HQ), a redox-
apiost HQ-iadui ,,4 e active metabolite ofbenzene, is toxic to the
,e, ,.""'*..e:---'X'' 5 stromal element of the bone marrow (5).
o|q||ffig.g55 .......... QkThomas and co-workers (6) reported that
long-term cultures of stromal macrophages
-.bone.mart.O~. ~are toHQ-induced cytotox-
icity than
a stromal fibroblastoid cell line.
Maintaining stromal macrophage viability
E 9 9 and function is important because the stro-
ntoe6de''c,,,,'e tpgrn-chowk4- mal macrophages synthesize and release
.ow-- interleukin-1, which in turn induces stro-
-D mal fibroblastoid and endothelial cells to
93)~produce colony-stimulating activity and
~~interleukins (IL) for myelopoiesis and lym-
~~~phopoiesis (7-9). Furthermore, noncyto-
,~~~~~~~~~~~~~~..,
toxic concentrations of HQ, which had no
........................................................ ~~~~~~effect on DNA or protein synthesis, pre-
vented conversion of the 34-kD pre-IL-ax
,e.... ..-..
..... ~~~to mature 17-kD cytokine in purified
murine bone marrow macrophages (10).
~~~~~~Recently it was shown that quinone
reductase (QR) activity and glutathione
...(GSH) concentration within stromal cells
~ ~ ~ ~ ~ reimportant determinants of susceptibili-
ty to HQ-induced cytotoxicity (6,11,12).
}- Quinone reductase is a widely distributed ..;.;................
cytosolic flavoprotein important in cellular
...................proc of quinones (13,14). In partic-
ular, QR catalyzes the two-electron reduc-
of quinones to hydroquinones, which
MF: ~~~~~~~~~are then amenable to glucuronidation and
excretion (15,16). Induction of glu-
..........tathione.aswell as phase enzymes,
~~~~~~~~..|....... ta h o e as ee.
.............including QR, is a useful mechanism to
..............enhance the detoxification of some chemi-
cally reactive intermediates (14). Quinone
...e f seee s reductase is coordinately induced with
............other.e -processing phase II
~~~~~~~enzymes, such as the glutathione-S-trans-
ferases (14,17,18). Recent studies by
~DeLong and co-workers (19) showed that
:ggyythe
in vitro induction of QR can protect
hepatoma cells against the toxicity of a
.......... ..........number of quinone xenobiotics. We
...
recently chemoprotective
nature of the induction of GSH and QR
activity against HQ-induced cytotoxicity
in bone marrow stromal cells (11,12,20).
In these previous studies, we used tert-
butylhydroquinone (tBHQ) and 1,2-dithi-
ole-3-thione (DTT) as inducing agents. In
the current study, only DTT was used as
the inducing agent because it does not
exhibit toxic effects against stromal cells in
vitro at concentrations up to 250 ,uM.
Additionally, DTT is classified as a mono-
functional inducer that does not require
interaction with the Ah receptor, which is
defective in the DBA/2 strain ofmouse, to
elicit in vitro or in vivo GSH and/or
enzyme induction (21,22).
The purposes ofthe current study were
to determine if DTT protects DBA/2-
derived stromal elements against the cyto-
toxic effects of HQ and if DTT also pro-
tects stromal cell functional activity by
supporting myelopoiesis (Fig. 1). Ad-
ditionally, in vivo induction ofQR activity
within the bone marrow compartment was
studied by feeding DTT to mice.
Methods
We obtained male DBA/2 mice (25-30 g)
from Jackson Laboratories (Bar Harbor,
ME) and housed them in an air-condi-
tioned room (700F) with a light period
from 6 AM to 6 PM. Purina laboratory
chow and water were available ad libitum
to all animals except those fed DTT.
Thomas Kensler of Johns Hopkins
University kindly provided the DTT [5-
(2-pyrazinyl)]-1,2-dithiole-3-thione (RP
33,851)]. We obtained gridded TC35 tis-
sue culture plates from Lux (Nunc, Inc.,
Naperville, IL). Microtiter plates and all
other tissue culture plasticware were
obtained from COSTAR (Van Nuys, CA).
We measured absorbencies in 96-well
microtiter plates with an automated optical
scanner equipped with a 610-nm filter
(Biotek, Winooski, VT). Dulbecco's mod-
ified Eagle medium (DMEM), fetal bovine
serum (FBS), L-asparagin, penicillin/strep-
tomycin, L-glutamine, trypsin, Dulbecco's
phosphate-buffered saline (PBS), and agar
were obtained from Gibco (Grand Island,
NY). We obtained CentriCell concentrat-
ing centrifuge kits (cat. Y18674-2 and
Y18674-8) from Polysciences, Inc.
(Warrington, PA). The antioxidant-free
diet used for DTT feeding studies was
powdered AIN-76 purified diet plus mena-
dione without ethoxyquin, and was pro-
cured from TEKLAD DIETS (TEKLAD,
Madison, WI). We obtained all other
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Figure 1. Strategies for chemoprotection against benzene and its metabolites in bone marrow, modified
from Wierda (40).
reagents from the Sigma Chemical Com-
pany (St. Louis, MO). We dissolved
hydroquinone in PBS immediately before
adding it to cell cultures to minimize oxi-
dation.
Isolation ofBone Marrow Cells and
Primary Adherent Stromal Cell Cul-
tures. Bone marrow cells were flushed
from the femurs of mice according to the
method of Oliver and Goldstein (23) and
pooled in either PBS or DMEM (no addi-
tions). The procedure used to establish
primary adherent stromal cell cultures was
a modification of the method of Zipori
and Bol (24). For adherent cell culture, we
pooled cell suspensions from two or more
animals and diluted them with DMEM
supplemented with 15% FBS, 2 mM glut-
amine, 50 jiM 2-mercaptoethanol, 100
,ug/ml L-asparagin, 100 IU/ml penicillin,
and 100 jig/ml streptomycin, and then
plated the suspensions on 100-mm tissue
culture dishes, six plates per two animals.
Twenty-four hours later, we gently aspirat-
ed media and replaced it. At 48 hr we
washed cultures twice with PBS to remove
unattached cells and debris. Cultures were
maintained in 100-mm tissue culture dish-
es, changing media every 5-6 days, until
they were used in microtiter plate and
other assays 10-18 days after isolation.
For all toxicity assays, we trypsinized cells
and replated them in 96-well microtiter
plates at a concentration of 3 x 104
cells/well.
Chemical Protection against Hydro-
quinone-induced Toxicity in Primary
Stromal Cells. We plated cells into 96-
well plates at 3 x I04 cells/well and treated
them with 75 jIM DTT 24 hr later. After
another 24 hr, we replaced the chemopro-
tector with HQ, and 24 hr later (a total of
72 hr after plating), we assayed cells for
survival with crystal violet staining as pre-
viously described (11). Peak induction of
QR activity occurs between 16 and 24 hr
after a single dose ofDTT, and it has been
determined that 75 jM DTT induces
essentially the maximal QR activities
observed in these cells after DTT treat-
ment (12). We report survival as percent
survival of treated: control groups, with
control cells representing 100% [(Abs610
treated cells/Abs6l0 control cells) x100].
In studies to determine ifDTT could pro-
tect against HQ inhibition of stromal cell
support ofmyelopoiesis, we pretreated pri-
mary cultures for 24 hr with 75 pM DTT,
removed DTT and replaced it with 20 piM
HQ, and conditioned and concentrated
the medium for CFU-G/M (colony-form-
ing units of granulocytes and monocytes)
assays as described below.
Assessment ofPreferential KiUling by
Hydroquinone ofMacrophages versus
Fibroblasts in DBA12-derived Primary
Stromal Cels. Six replicate TC 60 plates
per n (n refers to one discreet experi-
ment/observation) were seeded with 2 x
106 2-week-old stromal cells. One 96-well
microtiter plate per n was also seeded with
3 x 104 cells/well. We treated three
plates/n and three rows of wells/n 24 hr
later (day 2) with 75 jM DTT. On day 3,
we treated one plate or microtiter plate
row with 0, 35, or 50 jiM hydroquinone
(these doses ofHQ are the LC25 and LC50
doses for DBA/2 primary stromal cells).
Finally, on day 4, 72 hr after plating, we
collected cells in the TC60 plates by scrap-
ing and centrifugation and stained them for
esterase activity using two different sub-
strates, ct-naphthylacetate (nonspecific) and
cx-naphthylbutyrate (Sigma diagnostic kits
90-Al and 181-B). We assessed population
differentials by determining the percent
esterase-positive cells (macrophages) using
standard light microscopy. Cells in the
microtiter plates were stained with 0.4%
crystal violet to determine survival (11).
Assay ofDicoumarol-Inhibitable
Quinone Reductase Activity. Quinone
reductase (QR) activity was assayed by
modification of the microtiter plate proce-
dure developed by Prochaska and
Santamaria (25). In this procedure, QR
activity is assessed by measuring the di-
coumarol-inhibitable NADPH-dependent
menadiol-mediated reduction of 3-(4,5-
dimethylthiazo-2-yl)-2,5-diphenyltetrazoli-
um bromide (MTT) to the blue formazan
dye. For this assay we trypsinized stromal
cells, spun them at 1000 rpm for 10 min,
discarded the supernatant, and lysed the
cells by incubation at 370C for 10 min
with 0.8% digitonin in 2 mM EDTA, pH
7.8. We assessed dicoumarol-inhibitable
QR activity by adding the MTT reaction
mixture, described below, to digitonin-
lysed stromal cells in the presence and
absence of60 gv dicoumarol. We record-
ed the spectrophotometric kinetic mea-
surement of change in absorbance/min at
610 nm and calculated QR activity using
the extinction coefficient for MTT
(11,300M'1 cm') and expressed this value
as nmol MTT reduced/min/mg protein.
Protein was quantified by a modified
Lowry assay (26) or by the Bio-Rad pro-
tein assay (cat. no. 500-0006), which is
based on the Bradford assay (27). The
MTT reaction mixture consisted of 25
mM Tris-Cl, 0.67 mg/ml bovine serum
albumin, 0.01% Tween-20, 5 gM flavin
adenine dinucleotide, 1 mM glucose-6-
phosphate, 30 gM NADP, 2 units/ml glu-
cose-6-phosphate dehydrogenase, 0.3
mg/ml MTT, and 50 IM menadione.
Granulocyte/Monocyte Colony For-
mation in Soft Agar. We prepared con-
centrated lOX agar solution (3% w/v) by
dissolving 3 g agar (Gibco cat. no.
MOOO1O) in 100 ml distilled water and
sterilized it by autoclaving. For CFU-G/M
assays, bone marrow cells were harvested
into DMEM, with no additives, as de-
scribed previously, centrifuged, and nucle-
ated cells were counted by Coulter counter
using a red cell lysing agent, "zapaglobin."
We heated sterile lOX agar to boiling and
diluted it 1:10 (Cf 0.3% agar) with 390C
DMEM supplemented with 15% FBS, 2
mM glutamine, 50 ,uM 2-mercaptoeth-
anol, 100 ,ug/ml L-asparagin, 100 IU/ml
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We then added cells to the agar mixture in
no more than 100-p1 volumes to produce
nucleated cell concentrations ranging from
4 to 20 x 10 cells/ml. Next we added 1
ml of the cell-agar suspension to gridded
TC35 dishes containing 100 p1 ofmedium
containing colony-stimulating factor. The
colony-stimulating activity (CSA) was
derived from medium that had been con-
ditioned (12 days) by primary bone mar-
row stromal cells in the presence or ab-
sence of hydroquinone and/or DTT, as
described below. After plating the cell-agar
mixture, we allowed the agar to solidify at
room temperature and incubated cultures
at 370C in a humidified, 5% CO2 atmos-
phere for 8-12 days. Colonies consisting of
at least 50 cells were scored from four
replicate plates per test group using an
inverted phase-contrast microscope.
Hydroquinone Inhibition ofStromal
CellAbility to Support Myelopoiesis in
Soft Agar. The effect of noncytotoxic
doses of hydroquinone on the ability of
DBA/2-derived stromal cells to support
myelopoiesis was evaluated by treating
10-14-day cultures with 15 IM HQ and
allowing the treated cells to condition the
media for 12 days. We then collected this
conditioned media and concentrated it for
use in the CFU-G/M assay described
above. Because the HQ was not removed
during the media-conditioning period, we
also determined CFU-G/Ms with condi-
tioned media from untreated cells and
added 20 IM HQ at the time of the
colony-forming assay to control for any
effect that residual HQ may have had on
myelopoiesis (data not shown). Stromal
cell conditioned media was concentrated
approximately 10-fold in CentriCells
(Polysciences, Inc.) with a 30,000 molecu-
lar weight cut-off point. We centrifuged
the CentriCells at 2000g in a swinging-
bucket rotor for 30 min. After centrifuga-
tion, we determined the volume of the
least concentrated sample and added
DMEM with all additives to the other
samples to bring them up to this volume so
that all samples had an equal concentra-
tion. Individual CentriCells were used a
maximum of 3 times, and concentrated
volumes on any one run varied by ± 10%.
In Vivo Feeding ofDTT. We accli-
mated DBA/2 mice (9-10-week-old males)
and maintained them on an antioxidant-
free powdered diet (AIN-76 purified diet
with additional menadione and without
ethoxyquin, TEKLAD DIETS) for 1 week.
The test group was switched to diet con-
taining 0.1% DTT, a concentration which
was well tolerated by the animals based on
appearance, weight, and activity levels.
After 6 days on test or control diet, animals
were humanely euthanized by cervical dis-
location, and bone marrow and livers were
removed for enzyme analysis. We deter-
mined QR activity in whole bone marrow
and in 24-hr primary cultures of bone
marrow stromal cells. Livers were used as a
positive control for QR and glutathione-S-
transferase(GST) induction by DTT (data
not shown).
In experiments to determine if in vivo
feeding of 0.1% DTT could protect pri-
mary bone marrow cells against ex vivo
challenge by hydroquinone, we treated ani-
mals as described immediately above and
flushed bone marrow cells from the femurs
using two mice per n. Equal numbers of
nucleated cells were then plated into four
TC100 dishes per n in the presence (two
plates) or absence (two plates) of 50 P.M
HQ, the LC50 dose for DBA/2 primary
stromal cells. By this protocol each n had
two test plates and two control plates to
serve as its own control. Twenty-four
hours later, we washed plates four times
with PBS to remove dead and unattached
cells. We then collected surviving, at-
tached cells by scraping the plates with a
rubber scraper and assessed survival by
counting the number of surviving cells
using a Coulter counter. Data are ex-
pressed as percent ofsurvival for controls.
Statistics. Computations and statistics
were performed using Lotus and Statpak
software on an IBM personal computer.
We used Students t-test (two-tailed) and
one-way analysis of variance (ANOVA);
values were considered significantly differ-
ent ifp < 0.05 or ifthe Fratio had a signif-
icance < 0.05.
Results
Based on more extensive dose-response
studies, the LC50 for hydroquinone was
determined to be 49 ± 6 P.M for 3 x 104
stromal cells/well for DBA/2 (11).
Twenty-four hours ofpretreatment ofstro-
mal cells with 75 ,uM DTT protected
against HQ-induced cytotoxicity, even at
95 pM HQ, a concentration that killed all
cells in non-DTT-treated controls (12).
When DBA/2-derived stromal cells
were exposed to LC25 and LC50 concentra-
tions ofHQ and the proportion ofmacro-
phages versus fibroblasts to untreated cells
were compared, the proportion of macro-
phages in the HQ-treated cells dropped
from approximately 60% to about 40%,
indicating that the macrophages were more
sensitive to HQ than the fibroblasts (Table
1). This is consistent with results obtained
by Thomas and co-workers with cells
derived from B6C3F1 mice (6). At the
LC25 ofHQ, at which 25% ofthe cells are
killed, a 20% decrease in the macrophage
population means that virtually all the cells
that were killed were macrophages. In the
same experiment, another group of cells
was pretreated for 24 hr with 75 pM DTT
before exposure to HQ, and the percentage
of macrophages versus fibroblasts was
determined. DTT completely protected
the cells from the cytotoxic effects of HQ,
and the proportion of macrophages to
fibroblasts was identical to control popula-
tions (Table 1). As previously reported,
QR activity approximately doubles, and
GSH concentration increases by about
one-third after pretreatment with 75 pM
DTT (12). The increases in both GSH
concentration and QR activity would
therefore appear to underlie the chemopro-
tective actions of DTT. Mechanistically,
GSH would interact directly with the elec-
trophilic benzoquinone, whereas increased
QR activity would reduce benzoquinone to
the less chemically reactive hydroquinone.
The studies described thus far used
only cell death as the endpoint for toxicity
to HQ. Because the stromal element of
the bone marrow is involved in the regula-
tion and maintenance of hematopoiesis,
chemical toxicity could also be expressed
by impairment of regulatory function
without causing cell death. This form of
HQ-induced toxicity has recently been
reported in long-term stromal cultures
derived from the B6C3F1 mouse (28).
Consequently, we were interested to see if
DTT could protect primary stromal cells
from HQ-induced toxicity using this func-
tional endpoint as an assessment of toxici-
ty. Stromal cell support of myelopoiesis
can be assayed in two ways: by plating cells
in semisolid agar directly onto adhered
stromal cells or by plating cells in agar onto
media that has been conditioned by stro-
mal cells. Conditioned media has to be
Table 1. Effects of HQ on macrophage versus fibroblast differential in DBA/2 primary bone marrow stro-
mal cells
Survival (%) Esterase-positive cells(%)a
HQ concentration (IM) -DDT +DTT -DTT +DTTb
0 100 100 59±3b 58±2
35 72±3 108±1 38±2* 57±1 (NS)
50 53±8 99±5 40±1* 61 ±2(NS)
Values are means ± SEM, with an n2 3; NS, notsignificantly different from untreated control (-DTT, 0 HQ)
by one-wayANOVA, F= 0.883.
aMacrophages.
bCells pretreated with 75piM DTT24 hr before HQ administration.
*Significantly different from untreated control (-DTT, 0 HQ) by one-wayANOVA, F= 38.666.
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Table 2. DTT protection against HQ-induced inhibition of DBAN2 stromal cell-conditioned medium to sup-
port CFU-G/M colony formation
Stromal cell No. of coloniesa
Source of CSA treatment (mean ± SEM)
None NA 2 1
Stromal mediumb None 361 ±19
Stromal medium 15pM HQ 204±21*
Stromal medium 75 JIM DTT pretreatment 367 ±46 (NS)
followed by 15 l.M HQ
CSA, colony-stimulating activity; NA, not applicable; NS, not significantly different from number of
colonies grown in the presence of medium conditioned by untreated cells, by Student's t-test. Stromal
cultures were used to condition media for 12 days in the presence or absence of HQ and DTT.
a3 x 105 white blood cells were plated perTC35 dish in this colony-forming assay.
bConditioned medium was concentrated by centrifugation in Centricells to about 1/15 volume.
*Significantly differentfrom number of colonies grown in the presence of medium conditioned by untreat-
ed cells; Student's t-test, p<0.02.
concentrated to express enough colony-
stimulating activity to support myelo-
poiesis. We used the second method to
obtain the stromal cell-derived colony-
stimulating factors necessary for the sup-
port of myelopoiesis because conditioned
media has the additional advantage of
allowing us to treat the stromal cells with-
out concurrently treating the naive bone
marrow cells used in the colony-forming
assay.
The data presented in Table 2 illustrate
that 15 p.M HQ, which is a noncytotoxic
concentration for DBA/2-derived stromal
cells, impaired the ability of stromal cells
to support myelopoiesis as indicated by a
reduction in the number of colonies com-
pared to media obtained from untreated
cells. Pretreatment of the stromal cells
with 75 IM DTT 24 hr before exposure to
15 lM HQ protected the functional in-
tegrity of the stromal cells as indicated by
the ability of the conditioned medium to
support the growth ofthe same number of
colonies as untreated stromal cells. To
control for any effects that residual HQ or
DTT in the concentrated, stromal cell-
conditioned media may have had on col-
ony formation, a second series of colony-
forming experiments were performed. In
the second set ofexperiments, 20 M HQ
or 75 pM DTT was added to the condi-
tioned, concentrated media from untreated
stromal cells at the time ofassay for colony
formation. Conditioned media from stro-
mal cells treated with 20 pM HQwas also
assayed in this experiment. Neither 20 pM
HQnor 75 IAM DTT added at the time of
assay had any effect on colony formation
by naive bone marrow cells, and inhibition
of stromal cell ability to support myelo-
poiesis by noncytotoxic concentrations of
HQwas confirmed (data not shown).
The significant increase in QR activity
resulting from DTT exposure focused our
attention on this enzyme as a biomarker of
DTT inductive chemoprotective effects in
subsequent in vivo experiments. The final
series of experiments were designed to test
ifthe in vivo administration ofDTT could
induce QR activity in the bone marrow,
and if so, could in vivo feeding of DTT
protect bone marrow stromal cells from ex
vivo challenge with HQ. It was necessary
to remove the bone marrow cells from the
animals for HQchallenge rather than chal-
lenge the animals in vivo to demonstrate
definitively that relevant biochemical
changes had occurred in the target organ.
Demonstration of DTT protection against
in vivo HQ or benzene challenge would
require extensive pharmacokinetic analysis
to establish if protection resides solely at
the level ofthe bone marrow as opposed to
(or in addition to) other sites such as the
liver, as has been shown with oral benzo-
[a]pyrene-induced bone marrow toxicity
(29). In vivo feeding of DTT does induce
QR activity in rat liver (30).
DBA/2 mice were fed 0.1% DTT
mixed in the diet for 6 days. This dose of
DTT was well tolerated as assessed by
weight gain, activity levels, and overall
appearance, which were comparable to
control animals. At the end of the test
period, we euthanized animals and cul-
tured bone marrow cells for assessment of
QR activity or treatment. Livers were also
removed, perfused, and immediately frozen
in liquid nitrogen to be used as a positive
control, and 2- to 3-fold inductions ofQR
activity were observed (data not shown).
Induction of hepatic QR activity was
expected due to the fact that in vivo induc-
tion by a number of phase II inducers has
been demonstrated in the DBA/2 mouse
(22). As shown in Table 3, there was an
increase in QR activity in endogenous
bone marrow preparations as well as in 24-
hr stromal cultures. DTT feeding in-
creased QR activity in whole bone marrow
preparations from 17 to 22 nmol/min/mg
protein, and from 30 to 46 nmol/min/mg
protein in 24-hr stromal cells (Table 3). In
keeping with the induction ofQR activity
within the bone marrow compartment, in
vivo feeding of DTT protected primary
stromal cells against a subsequent in vitro
challenge with 50 jiM HQ during the first
24 hr in culture (Table 4).
Discussion
The concept of chemoprotection, that is,
protection from the toxicity of one chemi-
cal by the administration ofanother chem-
ical, was first observed more than 50 years
ago in rodents when skin tumors were pro-
duced by local applicatlion of carcinogens
(17,18). Mechanistically, chemoprotec-
tion has been associated with the induction
of three classes of detoxification enzymes:
enzymes involved in ascorbic acid biosyn-
thesis, the microsomal P450 class of
enzymes, and soluble, cytosolic enzymes
known collectively as phase II detoxifica-
tion enzymes (17,31). Extensive research
since that time has demonstrated that
induction of phase II enzymes as well as
Table 3. Effect of in vivofeeding of DTT on quinone reductase activity in DBA/2-derived whole bone mar-
row and bone marrow stromal cells
Quinone reductase activity
(nmol MTT reduced/min/mg protein)
Cell preparation Control 0.1% DTT in diet
Whole bone marrow 17 ± 1 22 ± 1*
Primary stromal cellsa 30 ±2 46 ± 2*
Values are means ±SEM, n > 3.
aCells were allowed to adhere for 24 hr, washed repeatedly to remove nonadherent cells, then collected
for assay.
Significantly differentfrom respective control by Student's t-test, p<0.05.
Table 4. In vivofeeding of DTT protects against ex vivo hydroquinone challenge in DBAN2-derived primary
bone marrow stromal cells
Survival (%)
Hydroquinone concentration (pM) Control 0.1% DTT in diet
0 100 100
50 37±4 62±6*
Animals were fed control ortest dietfor 6 days, and the bone marrow cells were flushed from femurs and
plated into stromal media containing 0 or 50 [tM HQ [2 animals/n, 2 plates/n (0 and 50 jM HQ), so that
each n had its own control]; 24 hr later, cells were washed repeatedly, attached (live) stromal cells were
collected by scraping and counted using a Coulter counter. Values are means ±SEM, n = 4.
*Significantly different from control survival by Student's t-test, p <0.02.
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glutathione is a useful strategy for enhanc-
ing the clearance and/or detoxification of
chemically reactive intermediates (14,
18,32). Quinone reductase (QR) has also
been shown to be coordinately induced
with other electrophile-processing phase II
enzymes such as glutathione-S-transferases
(14,17,18). Recently, the protection of
hepatoma cells against the toxicity of a
number of redox-active xenobiotics has
been linked to the in vitro induction of
QR (19). A class of chemicals currently
under extensive investigation as chemopro-
tective agents are the dithiolethiones (33).
Bone marrow is a target organ for toxi-
cities induced by a spectrum of chemicals
(34) including the environmental pollu-
tants benzene and benzo[a]pyrene (BaP)
(35). The stromal cell component from
bone marrow is particularly susceptible to
toxicity induced by several redox-active
metabolites of the hematotoxin benzene,
such as benzoquinone and HQ (12,28,36).
Consequently, it was ofgreat interest when
recent studies in our laboratory demon-
strated that bone marrow-derived stromal
cells could also be protected against hydro-
quinone-induced cytotoxicity by pretreat-
ing cells with the phase II enzyme inducer
DTT (12). This observation prompted us
to further examine whether the inducing
activity of DTT in bone marrow stroma
also protects against HQ-induced modula-
tion of stromal-dependent myelopoiesis.
In this study, we have also examined
whether in vivo feeding of DTT induces
QR activity within the stromal compart-
ment and as such protects against the in
vitro toxicity ofHQ.
As shown in Table 1, HQwas toxic to
DBA/2-derived bone marrow stroma and
demonstrated preferential killing of stro-
mal macrophages. Primary cultures of
bone marrow stroma are not a pure popu-
lation of one type of cell; these cultures
consist of a 60:40 mixture of resident
macrophages and fibroblastoid cells, re-
spectively (24,37). Primary stromal
macrophages were more sensitive to HQ
than the fibroblastoid stromal cells, as
illustrated by the shift in the ratio of
macrophages to fibroblasts from 60:40 to
40:60 after LC25 or LC50 doses of HQ
(Table 1). Pretreatment of the stromal
macrophages and fibroblasts with DTT
prevented this shift in ratio (Table 1).
The data described above complement
previous studies performed in our labora-
tory comparing QR and GST activities
and GSH concentration between cell types
within the bone marrow stroma and be-
tween strains of mice with differential sus-
ceptibility to HQ-induced cytotoxicity.
These previous studies demonstrated that
basal QR activity was lower in the stromal
macrophage versus the stromal fibroblast,
with activity for the mixed population
falling between the values for the individ-
ual cell types (12). The lower QR activity
in the more HQ-sensitive cell type mimic-
ked the difference in QR activity previous-
ly observed between whole stromal popula-
tions from strains ofmice with differential
sensitivity to HQ-induced toxicity (12).
These data also agree with previous data
evaluating the effect of DTT on stromal
cell QR and GST activities and cytosolic
GSH concentration. Treatment ofprima-
ry cells in vitro with 75 jM DTT resulted
in a 2-fold increase in QR activity in
DBA/2 stroma and about a one-third
increase in cytosolic GSH concentration
(12). Unlike other tissues (22,32), DTT
treatment ofprimary bone marrow stromal
cells had no inductive effect on GST activ-
ity. Thus, the increase ofboth GSH con-
centration and QR activity appear to be
important in the chemoprotection against
HQ-induced toxicity provided by DTT.
This hypothesis was substantiated by the
effects of dicoumarol, an inhibitor of QR
activity (31), on HQ toxicity and through
protection by DTT. Dicoumarol potenti-
ated HQtoxicity and interfered with DTT
protection against HQ-induced toxicity in
stromal cells (12,38). Likewise, depletion
ofGSH in stromal cells by buthionine sul-
foximine potentiated HQ-induced toxicity
(39).
Because enhanced stromal cell survival
was used as an index of chemoprotection
from HQ-induced toxicity, we thought it
was important to also examine a noncyto-
toxic functional endpoint of toxicity
induced by HQ. A potential target for
nonlethal toxicity is the ability of stromal
cells to support myelopoiesis, which is an
in vivo function ofthe stromal cells. It has
been previously demonstrated that purified
populations of bone marrow stromal
fibroblasts can support myelopoiesis to
only 50% of the number of colonies that
are supported by mixed populations of
stromal fibroblasts and stromal
macrophages. Purified stromal
macrophages cannot support significant
myelopoiesis (28). The data presented in
Table 2 demonstrate that noncytotoxic
concentrations ofHQ impaired the ability
ofstromal cells to support myelo-poiesis by
approximately 40%. This indicated again
that the stromal macrophage was the pref-
erential target of noncytotoxic concentra-
tions ofHQ, with the amount ofobserved
myelopoiesis being supported primarily by
stromal fibroblasts. This is in agreement
with the previous data demonstrating pref-
erential killing of stromal macrophages
over stromal fibroblasts by HQ (Table 1).
Pretreatment of cells by DTT protected
the primary stromal cells from both forms
ofHQ-induced toxicity (Tables 1 and 2).
Chemoprotection of primary bone
marrow stromal cells by DTT was also
observed after in vivo feeding of DTT.
Using QR as a biomarker of the inducing
effect of DTT within the bone marrow, a
1.5-fold increase in QR activity was ob-
served in 24-hr stromal cultures derived
from animals that had received 0.1% DTT
in the diet for 6 days (Table 3). This
inductive activity of DTT was reflected in
protection against the cytotoxic effects of
50 FM HQ in stromal cells derived from
DTT-treated animals compared to stromal
cells derived from animals that did not
receive DTTin vivo (Table 4). More
importantly, based on the data presented
in Table 2, a protective effect against HQ-
induced alterations in myelopoiesis would
also be expected. Thus, the inducibility of
cellular defense mechanisms and xenobiot-
ic-processing enzymes by chemoprotective
agents such as DTT may prove to be a use-
ful strategy in preventing chemically
induced cell dysfunction and death in the
bone marrow (Fig. 1). In this regard, one
of the advantages of an agent like DTT is
that it is a monofunctional inducer and as
such does not require interaction with the
Ah receptor for its inducing activity (22).
The availability of chemicals that function
as inducers primarily of phase II enzymes
independent of the Ah receptor is impor-
tant from the perspective that genetic dif-
ferences in the Ah locus are relevant to
humans as well as to different strains of
mice (21).
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